HLA-G
Showing 1 - 25 of 4,792
Solid Tumor Trial in Houston (Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide)
Not yet recruiting
- Solid Tumor
- Single Injection of IVS-3001- Anti - HLA-G CAR-T cells
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 19, 2023
Renal Cell Carcinoma, NSCLC, Pancreatic Adenocarcinoma, Colorectal Cancer Trial (RO7515629, tocilizumab)
Not yet recruiting
- Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer
- (no location specified)
Mar 3, 2023
Covid19 Trial in Suresnes (Baseline and during hospitalization blood samples, Baseline blood sample)
Completed
- Covid19
- Baseline and during hospitalization blood samples
- Baseline blood sample
-
Suresnes, FranceFoch hospital
Aug 2, 2022
Solid Tumor Trial in Taichung (HLA-G-CAR.BiTE allogeneic ?d T cells)
Not yet recruiting
- Solid Tumor
- HLA-G-CAR.BiTE allogeneic γδ T cells
-
Taichung, Non-US, TaiwanChina Medical University Hospital
Nov 27, 2023
Advanced Solid Tumor Trial in Beijing (YK0901 cells)
Not yet recruiting
- Advanced Solid Tumor
- YK0901 cells
-
Beijing, ChinaDepartment of GI Oncology, Peking University Cancer Hospital
Jun 27, 2023
Trifecta-Lung cfDNA-MMDx Study
Recruiting
- Lung Transplantation
-
Melbourne, Australia
- +5 more
Apr 18, 2023
Transplant-Related Hematologic Malignancy Trial in Atlanta (Sargramostim, Control Arm)
Recruiting
- Transplant-Related Hematologic Malignancy
- Sargramostim
- Control Arm
-
Atlanta, GeorgiaNorthside Hospital
Oct 19, 2022
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia Trial in Duarte, Atlanta (procedure, drug,
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +9 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +7 more
-
Duarte, California
- +1 more
Sep 22, 2023
Trifecta-Heart cfDNA-MMDx Study
Recruiting
- Heart Transplant Rejection
- MMDx diagnostic test
- +2 more
-
Los Angeles, California
- +9 more
Aug 2, 2022
Sickle Cell Disease Trial in Canada, United States (Alemtuzumab intravenously, low dose total body irradiation, Sirolimus)
Recruiting
- Sickle Cell Disease
- Alemtuzumab intravenously, low dose total body irradiation, Sirolimus
-
Washington, District of Columbia
- +5 more
Mar 2, 2022
Myeloid Malignancies Trial in Italy (GvHD prophylaxis)
Recruiting
- Myeloid Malignancies
- GvHD prophylaxis
-
Alessandria, Italy
- +32 more
Nov 23, 2022
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified
Recruiting
- Endometrial Cancer
- +8 more
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
-
Orlando, Florida
- +21 more
Feb 2, 2023
Relevance of the HLA-G Immune Checkpoint in Cancer Immunotherapy
Not yet recruiting
- Solid Tumor
- (no location specified)
Mar 6, 2020
Trifecta-Kidney cfDNA-MMDx Study
Recruiting
- Kidney Transplant Rejection
- MMDx
- +2 more
-
Tampa, Florida
- +30 more
Oct 12, 2022
Adult Solid Tumor Trial in Canada, Germany, United States (SQZ-PBMC-HPV, Atezolizumab, Ipilimumab)
Active, not recruiting
- Adult Solid Tumor
- SQZ-PBMC-HPV
- +3 more
-
Scottsdale, Arizona
- +12 more
Jan 17, 2023
Acute Myeloid Leukemia, Advanced MDS Trial in New York (Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin,
Completed
- Acute Myeloid Leukemia
- Advanced Myelodysplastic Syndromes
- Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Aug 27, 2021
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma Trial in Seattle (Allogeneic Hematopoietic
Recruiting
- Acute Lymphoblastic Leukemia
- +16 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 1, 2022
Acute Leukemia, MDS, T-lymphoblastic Lymphoma Trial (drug, radiation, procedure)
Not yet recruiting
- Acute Leukemia
- +6 more
- Cyclophosphamide
- +8 more
- (no location specified)
Dec 8, 2021
Tumor Antigen Expression Profiling and HLA Typing for
Recruiting
- Solid and Hematological Malignancies
-
Duarte, California
- +34 more
Aug 23, 2022
Urinary Bladder Cancer, Melanoma, Head Neck Cancer Trial in Canada, United States (Autologous genetically modified MAGE-A4?¹º³²T
Active, not recruiting
- Urinary Bladder Cancer
- +9 more
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
- Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
-
Miami, Florida
- +10 more
Aug 9, 2022